1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Alfresa Holdings Corporation

Alfresa Holdings Corporation

ARHCF
Alfresa Holdings CorporationUS flagOther OTC
11.87
USD
- -
- -
2.16BMarket Cap
Alfresa Holdings Corporation
ARHCF
(Other OTC)

Recent

price

11.87

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
11,142.34
10,746.34
11,392.31
11,204.2
11,315.3
10,824.31
11,711.63
11,777.42
12,012.93
12,398.25
12,748.7
12,332.8
12,338.56
13,322.54
14,905.63
15,950.69
7,655.29
Revenue per Share
56.8
32.42
32.24
97.48
115.5
102.48
158.99
142.57
164.25
195.91
190.26
115.75
153.57
127.42
154.13
147.54
94.75
Basic EPS, GAAP
-12.01
199.03
26.58
354.54
-218.69
89.08
107.25
95.69
162.49
155.94
62.61
-186.15
93.33
-61.17
370.49
-78.05
- -
Free Cash Flow per Basic Share
21.35
21.81
22.5
21.87
24
27.35
32.25
34
38
44.2
49
51
54.54
55.04
63.85
67.6
- -
Dividend per Share
751.8
696.12
694.56
742.91
806.02
874.11
1,019.34
1,142.56
1,271.34
1,439.64
1,588.33
1,653.08
1,767.86
1,902.98
2,101.24
2,252.26
2,194.73
Book Value per Share
1,166.55
1,128.6
1,158.87
1,281.2
1,337.52
1,535.59
1,608.2
1,752.58
1,955.88
1,983.1
2,160.29
2,232.32
2,161.81
2,324.83
2,415.8
2,536.02
2,541.65
Tangible Book Value per Share
185
203
205
213
221
224
220
217
217
213
212
212
210
202
192
186
187
Basic Weighted Avg Shares
2,059,328
2,183,356
2,333,465
2,387,435
2,504,574
2,421,105
2,576,360
2,551,919
2,602,925
2,640,529
2,698,555
2,610,521
2,585,643
2,696,069
2,858,500
2,961,051
1,430,644
Sales/Revenue/Turnover
0.71
0.43
0.4
0.99
1.4
1.21
1.76
1.3
1.6
1.7
1.77
1.07
1.13
1.12
1.35
1.29
1.57
Operating Margin (%)
8,237
9,340
9,308
10,819
10,011
9,374
10,850
11,017
10,564
10,756
11,777
11,868
12,824
13,302
13,514
14,923
- -
Depreciation Expense
10,497
6,587
6,604
20,771
25,566
22,922
34,975
30,893
35,589
41,724
40,273
24,501
32,182
25,786
29,558
27,389
17,708
Net Income, GAAP
48.56
51.32
56.82
39.06
40.84
38.42
34.6
30.44
30.75
31.8
31.93
32.95
33.16
33.17
32.47
30.29
33.11
Effective Tax Rate (%)
0.51
0.3
0.28
0.87
1.02
0.95
1.36
1.21
1.37
1.58
1.49
0.94
1.24
0.96
1.03
0.92
1.24
Profit Margin (%)
97,128
89,293
91,982
115,917
123,155
132,369
129,623
148,296
166,313
176,873
197,433
208,551
213,658
208,795
214,244
199,535
211,459
Working Capital
7,221
7,235
6,227
5,656
4,338
4,301
4,656
4,530
4,384
4,444
4,873
4,230
3,244
2,461
33,372
33,962
30,000
LT Debt
223,263
236,768
244,014
283,954
305,435
354,120
368,728
393,547
435,932
442,080
474,897
489,957
471,832
488,334
479,858
482,246
491,309
Total Equity
3.45
1.82
1.59
5.06
6.6
5.26
7.82
5.83
6.74
6.68
6.8
3.77
3.94
4.09
5.09
5.07
2.95
Return on Invested Capital (%)
7.01
4.18
4.05
12.77
14.52
11.81
15.86
12.59
13.2
13.97
12.23
7.01
8.8
6.75
7.16
6.17
4.22
Return on Capital (%)
8.17
4.7
4.66
13.82
15.19
12.26
16.66
13.1
13.61
14.34
12.53
7.14
8.93
6.83
7.5
6.67
4.42
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,565
- -
- -
LT Borrowings
30,000
- -
30,000
LT Finance Leases
3,372
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
187
- -
187
Market Capitalization
- -
- -
318,859

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
1,121,233
- -
1,125,071
Cash, Cash Equivalents & STI
213,756
- -
206,863
Accounts Receivable, Net
646,113
- -
652,172
Inventories
156,377
- -
164,966
Total Current Liabilities
906,989
- -
913,612
Payables & Accruals
- -
- -
- -
ST Debt
1,565
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.22%
0.35%
0.5%
Free Cash Flow
-149.43%
-300.92%
-120.39%
Net Income, GAAP
4.95%
-4.08%
-7.34%
Sales/Revenue/Turnover
2.08%
1.93%
3.59%
Total Cash Common Dividend
7.59%
3.97%
2.49%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
709,056
718,800
751,947
678,697
2,858,500
2025
- -
- -
- -
- -
2,961,051
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20.15
- -
- -
- -
154.13
2025
- -
- -
- -
- -
147.54
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
63.85
2025
- -
- -
- -
- -
67.6
2026
- -
- -
- -
- -
- -
Similar Companies
Nass Valley Gateway Ltd. (NVG.CN)
Yamashita Health Care Holdings,Inc. (9265.T)
Arzneiwerk AG VIDA (TLIK.F)
DocMorris AG (ZRSEF)
Oriola Oyj (OKDAV.HE)
McKesson Corporation (0JZU.L)
Business
Alfresa Holdings Corporation, established on September 29, 2003 and headquartered at 1-1-3 Otemachi, Chiyoda-ku, Tokyo, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import/export of pharmaceuticals, diagnostic reagents, medical devices and equipment; it operates dispensing pharmacies and related businesses as Japan's leading ethical pharmaceuticals wholesaler with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 2025. The company operates through six primary business segments: ethical pharmaceuticals wholesaling, which delivers pharmaceuticals, diagnostic reagents, medical devices, materials and nutritional foods from 207 nationwide distribution centers to hospitals, clinics and dispensing pharmacies; self-medication products wholesaling, providing over-the-counter drugs, health foods and supplements to drugstores and pharmacies as a total healthcare merchandising wholesaler; manufacturing, producing active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents and medical devices at eight bases compliant with GMP and QMS standards, including contract manufacturing; dispensing pharmacy and related businesses, operating 177 community-based family pharmacies supporting prevention to terminal care with home healthcare enhancements; regenerative medicine-related business, encompassing cell material supply, specified cell-processed products and CMO/CDMO services; and overseas business, featuring joint ventures like REMEJE PHARMACEUTICALS in China and Alfresa Codupha Healthcare Vietnam for medical devices and reagents primarily in Asia. Alfresa Holdings maintains a nationwide network across Japan with subsidiaries including Alfresa Corporation, Shikoku Alfresa, TS Alfresa, Tohoku Alfresa and others; it targets healthcare providers, pharmacies, drugstores and patients while advancing Total Supply Chain Services integrating development, manufacturing, distribution, sales and post-marketing surveillance. Recent developments include a March 2025 memorandum of understanding with Minaris Regenerative Medicine for collaborative cell therapy development, manufacturing and distribution utilizing Alfresa's logistics; a June 2025 strategic partnership and capital investment with HekaBio to accelerate biopharma and MedTech commercialization in CNS and regenerative medicine across Japan and Asia-Pacific; a November 2025 basic business alliance with K Pharma including investment in bonds with share warrants to establish iPS cell-derived regenerative medicine supply chains for products like KP8011; a January 2025 capital alliance with Medley via share exchange to bolster digital transformation synergies in pharmacy electronic records; and the May 2024 opening of the Tsukuba Distribution Center, alongside the launch of the 25-27 Mid-term Management Plan targeting ¥3.33 trillion net sales by fiscal 2027 under Vision 2032.